Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial

International Journal of Cancer

Volumn 98, Issue 2, 2002, Pages 268-273

  de Koning, Harry J ^a   Liem, Michael K ^a,b   Baan, Caroline A ^a   Boer, Rob ^a   Schröder, Fritz H ^a   Alexander, Freda E ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Institute for Health Sciences   (Netherlands)

Author keywords

Power; Prostate cancer; RCT; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CALCULATION; CANCER MORTALITY; CANCER SCREENING; EUROPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS;

AGED; EUROPE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC NEOPLASMS; SAMPLE SIZE;

EID: 0037051107     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10188     Document Type: Article

References (23)

1. Treatment of prostate cancer: Watchful waiting, radical prostatectomy, and cryoablation
2. Prospective evaluation plan for randomised trials of prostate cancer screening
3. Prostate cancer screening: What we know and what we need to know
4. Calculation of sample size in trials of screening for early diagnosis of disease
5. One and two sided tests of significance
6. Comparison of trends in prostate-cancer mortality in England and Wales and the USA
7. Downward trend in prostate cancer mortality in Quebec and Canada
8. Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the Federal State of Tyrol, Austria
9. Recent results of management of palpable clinically localized prostate cancer
10. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking
11. PSA-testing and use of DRE before and during a screening trial
12. Laboratory survey of Prostate Specific Antigen testing in Ontario
13. Breast cancer screening with mammography: Overview of Swedish randomised trials
14. Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands: Comparison with the United Kingdom
15. Why do men refuse or attend population-based screening for prostate cancer?
16. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute
17. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial
18. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction
19. Cost-effectiveness of shortening screening interval or extending age range of NHS breast screening programme: Computer simulation study
20. Large-scale randomized prostate cancer screening trials: Program performances in the ERSPC and PLCO trials (European Randomized Screening for Prostate Cancer and Prostate, Lung, Colorectal and Ovary cancer trials)